{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:08:31Z","timestamp":1791889711217,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Qingdao Applied Basic Research Program","award":["19-6-2-48-cg"],"award-info":[{"award-number":["19-6-2-48-cg"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The adipokine asprosin, which was recently discovered, facilitates hepatic glucose production. The aim of this study is to see whether serum asprosin concentrations are linked to diabetic nephropathy (DN).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed this investigation in a group of 212 type 2 diabetes (T2DM) patients. These patients were classified into three subgroups: DN0 group (normal to mildly increased), DN1 group (moderately increased), and DN2 group (severely increased) on the basis of urine albumin-to-creatinine ratio (ACR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>When compared to the controls, T2DM patients had higher serum asprosin levels. The DN2 group had significantly higher serum asprosin than the DN0 and DN1 groups. Furthermore, the DN1 group had higher serum asprosin than the DN0 group. Serum asprosin was linked to a higher risk of T2DM and DN in a logistic regression analysis. Serum asprosin was found to be positively related with disease duration, systolic blood pressure, blood urea nitrogen, creatinine, uric acid, ACR, calcium channel blockers, and angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker therapy, but negatively related with glomerular filtration rate, metformin, and acarbose therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Serum asprosin increase with the progression of DN. Serum asprosin is correlated with renal function and ACR.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-021-00668-x","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:13:54Z","timestamp":1620044034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Increased serum asprosin is correlated with diabetic nephropathy"],"prefix":"10.1186","volume":"13","author":[{"given":"Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibo","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"668_CR1","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/dme.12716","volume":"32","author":"SP Jansson","year":"2015","unstructured":"Jansson SP, Fall K, Brus O, Magnuson A, W\u00e4ndell P, \u00d6stgren CJ, et al. Prevalence and incidence of diabetes mellitus: a nationwide population-based pharmaco-epidemiological study in Sweden. Diabet Med. 2015;32:1319\u201328.","journal-title":"Diabet Med"},{"key":"668_CR2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/ggi.13534","volume":"18","author":"Y Kakio","year":"2018","unstructured":"Kakio Y, Uchida HA, Takeuchi H, Okuyama Y, Okuyama M, Umebayashi R, et al. Diabetic nephropathy is associated with frailty in patients with chronic hemodialysis. Geriatr Gerontol Int. 2018;18:1597\u2013602.","journal-title":"Geriatr Gerontol Int"},{"key":"668_CR3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc05-2470","volume":"29","author":"MC Eppens","year":"2006","unstructured":"Eppens MC, Craig ME, Cusumano J, Hing S, Chan AK, Howard NJ, et al. Prevalence of diabetes complications in adolescents with type 2 compared with type 1 diabetes. Diabetes Care. 2006;29:1300\u20136.","journal-title":"Diabetes Care"},{"key":"668_CR4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/dom.12630","volume":"18","author":"H Gallagher","year":"2016","unstructured":"Gallagher H, Suckling RJ. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab. 2016;18:641\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"668_CR5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/00365513.2019.1613673","volume":"79","author":"C Bellia","year":"2019","unstructured":"Bellia C, Cosma C, Lo Sasso B, Bivona G, Agnello L, Zaninotto M, et al. Glycated albumin as a glycaemic marker in patients with advanced chronic kidney disease and anaemia: a preliminary report. Scand J Clin Lab Invest. 2019;79:293\u20137.","journal-title":"Scand J Clin Lab Invest"},{"key":"668_CR6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.clinbiochem.2018.02.017","volume":"54","author":"C Bellia","year":"2018","unstructured":"Bellia C, Zaninotto M, Cosma C, Agnello L, Bivona G, Marinova M, et al. Clinical usefulness of glycated albumin in the diagnosis of diabetes: results from an Italian study. Clin Biochem. 2018;54:68\u201372.","journal-title":"Clin Biochem"},{"key":"668_CR7","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/10408363.2017.1377682","volume":"54","author":"N Papadopoulou-Marketou","year":"2017","unstructured":"Papadopoulou-Marketou N, Kanaka-Gantenbein C, Marketos N, Chrousos GP, Papassotiriou I. Biomarkers of diabetic nephropathy: a 2017 update. Crit Rev Clin Lab Sci. 2017;54:326\u201342.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"668_CR8","first-page":"488","volume":"49","author":"H Huang","year":"2019","unstructured":"Huang H, Li D, Huang X, Wang Y, Wang S, Wang X, et al. Association of complement and inflammatory biomarkers with diabetic nephropathy. Ann Clin Lab Sci. 2019;49:488\u201395.","journal-title":"Ann Clin Lab Sci"},{"key":"668_CR9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","volume":"165","author":"C Romere","year":"2016","unstructured":"Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566\u201379.","journal-title":"Cell"},{"key":"668_CR10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/nm.4432","volume":"23","author":"C Duerrschmid","year":"2017","unstructured":"Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444\u201353.","journal-title":"Nat Med"},{"key":"668_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cca.2017.10.034","volume":"489","author":"L Zhang","year":"2019","unstructured":"Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183\u20138.","journal-title":"Clin Chim Acta"},{"key":"668_CR12","first-page":"7375294","volume":"2018","author":"X Li","year":"2018","unstructured":"Li X, Liao M, Shen R, Zhang L, Hu H, Wu J, et al. Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases. Mediat Inflamm. 2018;2018:7375294.","journal-title":"Mediat Inflamm"},{"key":"668_CR13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jdi.13148","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang X, Jiang H, Ma X, Wu H. Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus. J Diabetes Investig. 2020;11:349\u201355.","journal-title":"J Diabetes Investig"},{"key":"668_CR14","first-page":"9471583","volume":"2018","author":"Y Wang","year":"2018","unstructured":"Wang Y, Qu H, Xiong X, Qiu Y, Liao Y, Chen Y, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediat Inflamm. 2018;2018:9471583.","journal-title":"Mediat Inflamm"},{"key":"668_CR15","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.2337\/dc21-S011","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. 11. Microvascular complications and foot care: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S151\u201367.","journal-title":"Diabetes Care"},{"key":"668_CR16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mce.2019.03.001","volume":"486","author":"T Lee","year":"2019","unstructured":"Lee T, Yun S, Jeong JH, Jung TW. Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation. Mol Cell Endocrinol. 2019;486:96\u2013104.","journal-title":"Mol Cell Endocrinol"},{"key":"668_CR17","doi-asserted-by":"crossref","first-page":"20888","DOI":"10.1002\/jcp.28694","volume":"234","author":"TW Jung","year":"2019","unstructured":"Jung TW, Kim HC, Kim HU, Park T, Park J, Kim U, et al. Asprosin attenuates insulin signaling pathway through PKC\u03b4-activated ER stress and inflammation in skeletal muscle. J Cell Physiol. 2019;234:20888\u201399.","journal-title":"J Cell Physiol"},{"key":"668_CR18","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cmet.2019.05.022","volume":"30","author":"E Li","year":"2019","unstructured":"Li E, Shan H, Chen L, Long A, Zhang Y, Liu Y, et al. OLFR734 mediates glucose metabolism as a receptor of asprosin. Cell Metab. 2019;30:319\u201328.","journal-title":"Cell Metab"},{"key":"668_CR19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ajem.2017.12.032","volume":"36","author":"AC Acara","year":"2018","unstructured":"Acara AC, Bolatkale M, K\u0131z\u0131lo\u011flu \u0130, \u0130bi\u015fo\u011flu E, Can \u00c7. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: asprosin. Am J Emerg Med. 2018;36:1504\u20135.","journal-title":"Am J Emerg Med"},{"key":"668_CR20","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.2147\/DMSO.S283413","volume":"13","author":"X Deng","year":"2020","unstructured":"Deng X, Zhao L, Guo C, Yang L, Wang D, Li Y, et al. Higher serum asprosin level is associated with urinary albumin excretion and renal function in type 2 diabetes. Diabetes Metab Syndr Obes. 2020;13:4341\u201351.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"668_CR21","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3389\/fimmu.2018.02918","volume":"9","author":"P Ahechu","year":"2018","unstructured":"Ahechu P, Zozaya G, Mart\u00ed P, Hern\u00e1ndez-Lizo\u00e1in JL, Baixauli J, Unamuno X, et al. NLRP3 inflammasome: a possible link between obesity-associated low-grade chronic inflammation and colorectal cancer development. Front Immunol. 2018;9:2918.","journal-title":"Front Immunol"},{"key":"668_CR22","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.3390\/ijms20143393","volume":"20","author":"K Matoba","year":"2019","unstructured":"Matoba K, Takeda Y, Nagai Y, Kawanami D, Utsunomiya K, Nishimura R. Unraveling the role of inflammation in the pathogenesis of diabetic kidney disease. Int J Mol Sci. 2019;20:3393.","journal-title":"Int J Mol Sci"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-021-00668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-021-00668-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-021-00668-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:28:49Z","timestamp":1620044929000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-021-00668-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1186\/s13098-021-00668-x","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"10 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The hospital ethics board of Qilu Hospital approved this report. Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the paper publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"51"}}